Evaluating an approach for communicating integrated risk scores for melanoma
- PMID: 39613910
- PMCID: PMC11985965
- DOI: 10.1038/s41431-024-01750-4
Evaluating an approach for communicating integrated risk scores for melanoma
Abstract
Integrated risk scores (polygenic and non-genetic risk factors) can facilitate risk-stratification, to inform targeted melanoma screening. This mixed-methods pilot study assessed satisfaction, attitudes, and psychosocial impact of a protocol for communicating integrated risk for melanoma using questionnaires (baseline and 1-month post-results) and semi-structured interviews. Affected and unaffected adults enroled in ongoing melanoma studies were recruited to receive their integrated risk booklets and attend a genetic counselling appointment. 35/73 consented to participate; 31 and 33 completed baseline and follow-up questionnaires, respectively. Participants rated the information as useful, felt it motivated favourable health behaviours and were satisfied with the quality and content of the booklet. All participants felt highly empowered managing melanoma risk at baseline and follow-up. Most participants were unsure or felt little to no control over preventing future melanomas, which did not change at follow-up (Chi-square p = 0.73). Genetic-specific distress, and uncertainty was low for all participants post-results. Qualitative interviews supported quantitative findings and highlighted importance of access to a clinician for results interpretation and risk-management. In this high-risk cohort, the communication model was acceptable, and did not result in negative psychosocial sequelae. Findings from this study highlight key considerations for effective communication and delivery of integrated risk which can be used to inform future research in more diverse cohorts for melanoma and other common conditions.
© 2024. The Author(s), under exclusive licence to European Society of Human Genetics.
Conflict of interest statement
Competing interests: HPS is a shareholder of MoleMap NZ Limited and Ederm-consult GmbH and undertakes regular teledermatological reporting for both companies. HPS is a medical consultant for Canfield Scientific, Inc; MoleMap Australia Pty Ltd; Blaze Bioscience, Inc; and Revenio Research Oy and is a medical advisor for First Derm. DGB is employed by Color Health, Inc, a company that returns polygenic scores results. All other authors declare no conflicts of interest. Ethics approval: Ethics and governance approval for study was granted by the Metro South Human Research Ethics Committee: HREC/2021/QMS/69781. Participation in this study was voluntary, and informed consent was obtained via signed consent forms.
References
-
- Melanoma Institute Australia. Melanoma Facts and Statistics. 2022. Available from: https://www.melanoma.org.au/understanding-melanoma/melanoma-facts-and-st....
-
- Australian Institute of Health and Welfare. Cancer data in Australia. 2023. Available from: https://www.aihw.gov.au/reports/cancer/cancer-data-in-australia/contents....
-
- National Cancer Control Indicators (Cancer Australia). Relative survival by stage at diagnosis (melanoma). 2019. Available from: https://ncci.canceraustralia.gov.au/outcomes/relative-survival-rate/rela....
-
- Garbe C, Dummer R, Amaral T, Amaria RN, Ascierto PA, Burton EM, et al. Neoadjuvant immunotherapy for melanoma is now ready for clinical practice. Nat Med. 2023;29:1310–2. - PubMed
-
- Wernli KJ, Henrikson NB, Morrison CC, Nguyen M, Pocobelli G, Blasi PR. Screening for skin cancer in adults updated evidence report and systematic review for the US preventive services task force. JAMA J Am Med Assoc. 2016;316:436–47. - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical